Leukemia Clinical Trials in Houston

Showing 761-780 of 1,657 trials

WITHDRAWNPhase 1< 1 mile

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

NCT01239108

Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.

Relapsed/Refractory Leukemias

Astex Pharmaceuticals, Inc.Started Oct 2010

Houston, Texas, United States

TERMINATEDPhase 1/2< 1 mile

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

NCT00522990

The goal of this clinical research study is to find the highest tolerable dose of AT9283 that can be given to patients who have ALL, AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with myeloid metaplasia. Researchers want to perform pharmacokinetic (PK) testing on blood to find out how quickly the study drug leaves the body and how the body breaks down the drug. The safety and effectiveness of this drug will also be studied.

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid Leukemia+2 more

Astex Pharmaceuticals, Inc.48 participantsStarted Sep 2006

Birmingham, Alabama, United States • Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00042003

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Chronic Myelogenous Leukemia

Astex Pharmaceuticals, Inc.40 participantsStarted Jul 2002

Duarte, California, United States • Escondido, California, United States • Los Angeles, California, United States +5 more locations

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Leukemia Trials in Other Cities

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

The clonoSEQ® Watch Registry

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

Other Conditions in Houston